Menu

Lab Test

Rheumatology / Immunology

Lyme Disease Serology (ELISA, Western Blot)

Tests for antibodies to Borrelia burgdorferi, the cause of Lyme disease, which can cause inflammatory arthritis.

Normal Range
Negative
Estimated Cost
Not specified
Book Diagnostic Visit
Medical Disclaimer The information provided in this comprehensive diagnostic guide is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician regarding test results.

Lyme Disease Serology: An Expert Guide to ELISA and Western Blot Testing

Lyme disease, caused by the bacterium Borrelia burgdorferi and transmitted through the bite of infected ticks, is the most common vector-borne illness in the Northern Hemisphere. Its diverse clinical manifestations, ranging from a characteristic skin rash (erythema migrans) to severe neurological, cardiac, and arthritic complications, make accurate diagnosis crucial. While early-stage Lyme disease with classic erythema migrans can often be diagnosed clinically, serological testing plays a pivotal role in confirming the diagnosis in later stages or when the initial presentation is atypical.

This comprehensive guide delves into the intricacies of Lyme disease serology, specifically focusing on the Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot tests. We will explore what these tests measure, their technical specifications, clinical indications, interpretation, specimen collection, and the various factors that can influence their results.

Comprehensive Introduction & Overview

Lyme disease diagnosis often relies on a combination of clinical assessment and laboratory testing. Serological tests detect antibodies produced by the body in response to a Borrelia burgdorferi infection. It's important to understand that these tests do not detect the bacteria itself, but rather the immune system's reaction to it.

The Centers for Disease Control and Prevention (CDC) recommends a two-tier testing algorithm for Lyme disease serology:

  1. Tier 1: Screening Test (ELISA or IFA)

    • The initial step typically involves an Enzyme-Linked Immunosorbent Assay (ELISA) or, less commonly, an Indirect Immunofluorescence Assay (IFA). These tests are highly sensitive, meaning they are good at detecting the presence of antibodies if an infection has occurred. However, their specificity can be lower, leading to potential false-positive results.

  2. Tier 2: Confirmatory Test (Western Blot)

    • If the initial ELISA or IFA test is positive or equivocal (uncertain), a Western Blot test is performed. The Western Blot is a more specific test that helps confirm the presence of Borrelia burgdorferi antibodies by detecting them against specific bacterial proteins. This two-tier approach significantly improves the overall accuracy of serological diagnosis, minimizing false positives while maintaining good sensitivity.

The antibodies measured are primarily:
* IgM (Immunoglobulin M): Typically appears early in the infection (2-4 weeks after exposure), peaks around 3-6 weeks, and then declines.
* IgG (Immunoglobulin G): Appears later (weeks to months after infection), can persist for many months or years, even after successful treatment.

Deep-Dive into Technical Specifications & Mechanisms

Understanding the mechanics of ELISA and Western Blot is crucial for interpreting their results accurately.

Enzyme-Linked Immunosorbent Assay (ELISA)

  • What it measures: ELISA tests for the presence of IgM and/or IgG antibodies in the patient's serum that react with antigens from Borrelia burgdorferi.
  • Mechanism:
    1. Wells in a microtiter plate are coated with Borrelia burgdorferi antigens.
    2. Patient serum is added to the wells. If Borrelia antibodies are present, they will bind to the antigens.
    3. The wells are washed to remove unbound antibodies.
    4. An enzyme-linked anti-human antibody (conjugate) is added. This conjugate binds to any patient antibodies that are attached to the Borrelia antigens.
    5. A substrate is added, which reacts with the enzyme on the conjugate to produce a color change.
    6. The intensity of the color change is measured spectrophotometrically and is proportional to the amount of Borrelia antibodies present.
  • Strengths: High sensitivity, relatively inexpensive, amenable to high-throughput screening.
  • Limitations: Can have cross-reactivity with antibodies from other infections or autoimmune conditions, leading to false positives. Not sufficiently specific on its own for definitive diagnosis.

Western Blot (Immunoblot)

  • What it measures: Western Blot identifies specific IgM and IgG antibodies that recognize individual protein components (antigens) of Borrelia burgdorferi. This provides a more detailed and specific antibody profile than ELISA.
  • Mechanism:
    1. Borrelia burgdorferi proteins are separated by size using gel electrophoresis.
    2. The separated proteins are transferred (blotted) onto a nitrocellulose membrane.
    3. The membrane is cut into strips. Patient serum is incubated with these strips. If specific Borrelia antibodies are present, they will bind to their corresponding protein bands on the strip.
    4. The strips are washed, and an enzyme-linked anti-human antibody is added, binding to any patient antibodies.
    5. A substrate is added, causing a visible colored band to appear wherever the enzyme is present, indicating antibody binding to a specific Borrelia protein.
  • Interpretation of Bands (CDC Criteria):
    • IgM Western Blot: Considered positive if at least 2 of 3 specific bands are present (23 kDa [OspC], 39 kDa, 41 kDa [flagellin]). IgM positivity alone is generally only considered indicative of acute infection if symptoms have been present for 30 days or less.
    • IgG Western Blot: Considered positive if at least 5 of 10 specific bands are present (18 kDa, 28 kDa, 30 kDa, 39 kDa, 41 kDa [flagellin], 45 kDa, 58 kDa, 66 kDa, 93 kDa).
  • Strengths: High specificity, helps confirm true Borrelia infection by identifying antibodies to distinct bacterial proteins. Essential for the two-tier testing algorithm.
  • Limitations: More complex and expensive than ELISA. Can still have some cross-reactivity, especially with the 41 kDa (flagellin) band, which is common to many bacteria. Requires careful interpretation based on specific band patterns.

The Two-Tier Testing Algorithm

The CDC-recommended two-tier approach is critical for accurate diagnosis:

  • Step 1: Perform an ELISA (or IFA).
  • Step 2: If the ELISA is positive or equivocal, perform a Western Blot (both IgM and IgG).
  • Result Interpretation:
    • Positive: Positive ELISA followed by positive Western Blot (meeting CDC criteria for IgM and/or IgG).
    • Negative: Negative ELISA. (No further testing needed).
    • Indeterminate: Positive ELISA but indeterminate or negative Western Blot, or Western Blot results not meeting criteria. May require retesting or clinical re-evaluation.

This sequential testing maximizes sensitivity (with ELISA) and then specificity (with Western Blot), significantly reducing the rate of false-positive diagnoses.

Extensive Clinical Indications & Usage

Lyme disease serology tests are not for everyone. Their use must be guided by clinical suspicion and epidemiological factors.

When to Order Lyme Serology: Detailed Clinical Indications

Serological testing for Lyme disease is indicated in individuals who present with:

  1. Symptoms consistent with later stages of Lyme disease:

    • Neurological Lyme disease: Facial palsy (Bell's palsy), meningitis, radiculopathy, peripheral neuropathy, encephalopathy (e.g., cognitive impairment, mood changes).
    • Lyme arthritis: Recurrent, brief attacks of objective joint swelling and pain, especially in large joints like the knee.
    • Lyme carditis: Atrioventricular heart block, myocarditis, pericarditis.
    • Acrodermatitis chronica atrophicans: A rare, chronic skin manifestation seen primarily in Europe.

  2. Symptoms consistent with early disseminated Lyme disease:

    • Multiple erythema migrans lesions.
    • Unexplained fatigue, muscle aches, headaches, or lymphadenopathy in the context of potential exposure and without a clear alternative diagnosis.

  3. Potential exposure to Borrelia burgdorferi:

    • History of a tick bite (though often not recalled).
    • Residence in or recent travel to an endemic area for Lyme disease (e.g., Northeastern, Mid-Atlantic, and Upper Midwestern United States; parts of Europe and Asia).

When Not to Order Lyme Serology: Contraindications & Misuse

Avoid testing in the following scenarios, as it can lead to misdiagnosis, anxiety, and inappropriate treatment:

  • Asymptomatic individuals: Routine screening of individuals without symptoms or known exposure is not recommended.
  • Individuals with non-specific symptoms: Fatigue, generalized aches, or "brain fog" without other objective signs of Lyme disease or known exposure are poor indicators for testing. These symptoms are common in many conditions.
  • Early, classic erythema migrans: A clinical diagnosis of erythema migrans is sufficient for treatment. Serology is often negative in the first few weeks of infection (the "window period") and should not delay treatment.
  • Monitoring treatment efficacy: Serology is generally not useful for monitoring treatment response. Antibody levels (especially IgG) can remain elevated for months or years after successful treatment, and a positive test does not necessarily indicate active infection or treatment failure.
  • Confirmation of a previous positive test without new symptoms: A previously positive test may reflect past exposure, not active disease.

Important Considerations for Interpretation

  • Clinical context is paramount: A positive serology test alone does not diagnose active Lyme disease. The results must always be interpreted in conjunction with the patient's symptoms, medical history, and risk of exposure.
  • Timing of testing: Antibodies take time to develop. Testing too early (within the first few weeks of infection) may yield a false-negative result, as seroconversion has not yet occurred.
  • Geographic location: Lyme disease is geographically restricted. A positive test in a non-endemic area without travel history is less likely to represent true Lyme disease.

Reference Ranges and Interpretation

Lyme disease serology results are typically reported as "Positive," "Negative," or "Equivocal/Indeterminate."

Interpreting Results:

| Test Result (Two-Tier Algorithm) | Interpretation | Clinical Action # Lyme Disease Serology: An Expert Guide to ELISA and Western Western Blot Testing

Comprehensive Introduction & Overview

Lyme disease, caused by the bacterium Borrelia burgdorferi and transmitted through the bite of infected ticks, is the most common vector-borne illness in the Northern Hemisphere. Its diverse clinical manifestations, ranging from a characteristic skin rash (erythema migrans) to severe neurological, cardiac, and arthritic complications, make accurate diagnosis crucial. While early-stage Lyme disease with classic erythema migrans can often be diagnosed clinically, serological testing plays a pivotal role in confirming the diagnosis in later stages or when the initial presentation is atypical.

This comprehensive guide delves into the intricacies of Lyme disease serology, specifically focusing on the Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot tests. We will explore what these tests measure, their technical specifications, clinical indications, interpretation, specimen collection, and the various factors that can influence their results. Our aim is to provide an authoritative resource for healthcare professionals and patients seeking to understand this critical diagnostic tool.

Deep-Dive into Technical Specifications / Mechanisms

Understanding the mechanics of ELISA and Western Blot is crucial for interpreting their results accurately. These tests detect antibodies produced by the body in response to a Borrelia burgdorferi infection, rather than detecting the bacteria itself.

Enzyme-Linked Immunosorbent Assay (ELISA)

The ELISA is typically the first step in the two-tier testing algorithm for Lyme disease.

  • What it Measures: ELISA tests for the presence of IgM (Immunoglobulin M) and/or IgG (Immunoglobulin G) antibodies in the patient's serum that react with antigens from Borrelia burgdorferi.
  • Mechanism:
    1. Antigen Coating: Wells of a microtiter plate are coated with purified Borrelia burgdorferi antigens (proteins or whole cell lysates).
    2. Sample Addition: A diluted sample of the patient's serum is added to these wells. If Borrelia antibodies (IgM or IgG) are present in the serum, they will bind specifically to the antigens coated on the well.
    3. Washing: The wells are thoroughly washed to remove any unbound antibodies or other serum components.
    4. Conjugate Addition: An enzyme-linked anti-human antibody (e.g., anti-human IgM or anti-human IgG, conjugated with an enzyme like horseradish peroxidase) is added. This conjugate will bind to the patient's antibodies that are already attached to the Borrelia antigens.
    5. Second Wash: Another wash step removes unbound conjugate.
    6. Substrate Addition: A chromogenic (color-producing) substrate is added. The enzyme attached to the conjugate catalyzes a reaction with the substrate, producing a color change.
    7. Detection: The intensity of the color change is measured spectrophotometrically. A higher optical density (more intense color) indicates a greater concentration of Borrelia antibodies in the patient's serum.
  • Sensitivity vs. Specificity: ELISA is highly sensitive, meaning it's good at detecting the presence of antibodies if an infection has occurred (low false-negative rate). However, its specificity can be lower, leading to potential false-positive results due to cross-reactivity with antibodies from other infections or autoimmune conditions.
  • Role in Two-Tier Testing: Due to its sensitivity, ELISA serves as an effective screening tool. A negative ELISA generally rules out Lyme disease in patients with symptoms >4-6 weeks (as antibodies would have developed by then). A positive or equivocal ELISA necessitates further confirmation with a Western Blot.

Western Blot (Immunoblot)

The Western Blot is the confirmatory test, performed only if the ELISA is positive or equivocal. It offers greater specificity.

  • What it Measures: Western Blot identifies specific IgM and IgG antibodies that recognize individual protein components (antigens) of Borrelia burgdorferi. This provides a more detailed and specific antibody profile than ELISA.
  • Mechanism:
    1. Antigen Preparation: Borrelia burgdorferi antigens are extracted and separated by molecular weight using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This separates the bacterial proteins into distinct bands.
    2. Blotting: The separated proteins are then electrically transferred (blotted) from the gel onto a nitrocellulose or polyvinylidene fluoride (PVDF) membrane. This membrane now has distinct bands of Borrelia proteins at different molecular weights.
    3. Membrane Strips: The membrane is cut into individual strips, each representing a full range of Borrelia proteins.
    4. Patient Serum Incubation: Each strip is incubated with a diluted sample of the patient's serum. If specific Borrelia antibodies are present, they will bind to their corresponding protein bands on the strip.
    5. Washing: Unbound antibodies are washed away.
    6. Conjugate Addition: An enzyme-linked anti-human antibody (specific for IgM or IgG) is added, which binds to any patient antibodies already attached to the protein bands.
    7. Substrate Addition & Detection: A chromogenic substrate is added. The enzyme catalyzes a reaction, producing a visible colored band wherever the enzyme is present, indicating antibody binding to a specific Borrelia protein.
  • Interpretation of Bands (CDC Criteria): Interpretation relies on identifying specific bands corresponding to known Borrelia proteins.
    • IgM Western Blot: Considered positive if at least 2 of the following 3 specific bands are present: 23 kDa (OspC), 39 kDa, and 41 kDa (flagellin). IgM positivity alone is generally considered indicative of acute infection if symptoms have been present for 30 days or less. Isolated IgM positivity lasting longer than 30 days is typically considered a false positive or non-specific.
    • IgG Western Blot: Considered positive if at least 5 of the following 10 specific bands are present: 18 kDa, 28 kDa, 30 kDa, 39 kDa, 41 kDa (flagellin), 45 kDa, 58 kDa, 66 kDa, and 93 kDa. IgG antibodies typically appear later in the infection and can persist for years.
  • Role in Two-Tier Testing: Western Blot provides the specificity needed to confirm an ELISA result. By identifying antibodies to multiple, distinct Borrelia proteins, it differentiates true infection from non-specific reactivity.

Summary of Antibody Kinetics:

  • IgM Antibodies: Develop within 2-4 weeks of infection, peak around 3-6 weeks, and then typically decline. They are most useful for diagnosing early acute infection.
  • IgG Antibodies: Appear later, usually 4-6 weeks after infection, and can persist for months to years, even after successful treatment. They are indicative of current or past infection.

Extensive Clinical Indications & Usage

Lyme disease serology tests are powerful tools but must be used judiciously. Misapplication can lead to misdiagnosis, unnecessary anxiety, and inappropriate treatment.

Detailed Clinical Indications for Ordering Lyme Serology

Lyme disease serology should be ordered for individuals who meet specific criteria, combining clinical suspicion with potential exposure.

  1. Objective Signs and Symptoms Consistent with Lyme Disease:
Share this guide: